[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置：首页 > 精选文章

International Journal of Clinical Research. 2024; 8: (2) ; 10.12208/j.ijcr.20241036 .

Progress in research on the treatment of recurrent nasopharyngeal carcinoma
复发性鼻咽癌的治疗研究进展

作者： 高碧玮1, 许瑞莲2 *

1 暨南大学第二临床医学院 广东深圳

2 深圳市人民医院肿瘤内科 广东深圳

*通讯作者： 许瑞莲,单位： 深圳市人民医院肿瘤内科 广东深圳；

引用本文: 高碧玮, 许瑞莲 复发性鼻咽癌的治疗研究进展[J]. 国际临床研究杂志, 2024; 8: (2) : 7-10.
Published: 2024/2/22 17:42:23

摘要

随着近年来放疗技术、手术方式及内科治疗的不断进步发展，鼻咽癌患者的治疗疗效已显著提高，但仍约20%～30%的鼻咽癌患者在初治后会出现局部和/或颈部淋巴结的复发或远处转移，这一问题成为当前医学界的重要挑战。再程放疗、手术治疗、全身系统治疗等方法均可以有效地提高鼻咽癌复发患者的生存率，本文就复发性鼻咽癌的诊断及治疗方式研究现状展开综述。

关键词： 复发性鼻咽癌；再程放疗；挽救性手术；研究进展

Abstract

With the continuous progress of radiotherapy technology, surgery and internal medicine treatment in recent years, the therapeutic efficacy of nasopharyngeal cancer patients has been significantly improved, but about 20%-30% of nasopharyngeal cancer patients will have recurrence or distant metastasis in local and/or cervical lymph nodes after primary treatment, which has become an important challenge in the medical field at present. Reprogrammed radiotherapy, salvage surgery, chemotherapy, targeted therapy and immunotherapy can effectively improve the survival rate of patients with recurrent nasopharyngeal cancer, and this article reviews the current status of research on the diagnosis and treatment modalities of recurrent nasopharyngeal cancer.

Key words： Recurrent nasopharyngeal carcinoma; Re-radiotherapy; Salvage surgery; Research progress

参考文献 References

[1] Hyuna S ,Jacques F ,L. R S , et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA: A Cancer Journal for Clinicians,2021.

[2] Chen Y P , Chan A T C , Le Q T ,et al. Nasopharyngeal carcinoma[J].The Lancet, 2019, 394(10192):64-80.

[3] Su S F , Han F , Zhao C ,et al. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy[J]. Chinese journal of cancer, 2011, 30(8):565-73.

[4] Xu T , Tang J , Gu M ,et al. Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.[J].Current Oncology, 2013, 20(5):E406-E419.

[5] Teo P T H , Tan N I C , Khoo J .Imaging appearances for recurrent nasopharyngeal carcinoma and post-salvage nasopharyngectomy[J].Clin Radiol, 2013(11).

[6] Yen R F , Hung R L , Pan M H ,et al.18-Fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging[J].Cancer, 2010, 98(2):283-287.

[7] Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy[J].Chinese Journal of Cancer, 2017.

[8] Sun X S , Liang Y J , Jia G D ,et al. Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinoma[J].Oral oncology, 106:104711 [2024-03-11].

[9] Hai-Yan C , Xiu-Mei M , Ming Y ,et al. Effectiveness and Toxicities of Intensity-Modulated Radiotherapy for Patients with Locally Recurrent Nasopharyngeal Carcinoma[J].Plos One, 2013, 8(9):e73918.

[10] Kong L , Wang L , Shen C ,et al. Salvage Intensity Modulated Radiation Therapy (IMRT) for Locally Recurrent Nasopharyngeal Cancer After Definitive IMRT: Treatment Outcomes of a Clinically Distinct Condition in the Modern Era[J].International Journal of Radiation Oncology Biology Physics, 2016, 96(2):E329-E329.

[11] Kong F F , Zhou J , Du C ,et al. Long-Term Survival and Late Complications of Intensity-Modulated Radiation Therapy for Recurrent Nasopharyngeal Carcinoma[J]. International Journal of Radiation Oncology*Biology *Physics, 2018, 102(3):e293-.

[12] Lin R , Slater J D , Yonemoto L T ,et al.Nasopharyngeal Carcinoma: Repeat Treatment with Conformal Proton Therapy—Dose-Volume Histogram Analysis1[J]. radio-logy, 1999, 213(2): 489-494.

[13] Feehan P E , Castro J R , Phillips T L ,et al. Recurrent locally advanced nasopharyngeal carcinoma treated with heavy charged particle irradiation.[J].International Journal of Radiation Oncology Biology Physics, 1992, 23(4):881-4.

[14] Hu J , Huang Q , Gao J ,et al.Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma[J].Cancer, 2020.

[15] Hai-Yan C , Xiu-Mei M , Ming Y ,et al. Effectiveness and Toxicities of Intensity-Modulated Radiotherapy for Patients with Locally Recurrent Nasopharyngeal Carcinoma[J].Plos One, 2013, 8(9):e73918.

[16] William,I,Wei,et al.Surgical salvage of persistent or recurrent nasopharyngeal carcinoma with maxillary swing approach - Critical appraisal after 2 decades[J].Head & Neck, 2010, 33(7).

[17] 徐文瑞,姜彦.复发鼻咽癌挽救性手术方法研究进展[J].山东大学耳鼻喉眼学报, 2019, 33(2):4.

[18] B Y P L A , A Y H W , D J T ,et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial[J]. 2021.

[19] Ho,Wai-kuen,Chan,et al.Early results of robotic assisted nasopharyngectomy for recurrent nasopharyngeal carcinoma[J]. Head & Neck Journal for the Sciences & Specialities of the Head & Neck, 2015.

[20] Zhang L , Huang Y , Hong S .Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial (vol 388, pg 1883, 2016)[J].The Lancet, 2016(10054):388.

[21] Hu J , Bao C , Gao J ,et al.Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results[J].Wiley-Blackwell Online Open, 2018(11).

[22] Guan Y , Liu S , Wang H Y ,et al. Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma[J]. Chinese Journal of Cancer, 2016.

[23] Zhang Y , Zhao L , Huang P ,et al. Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy[J]. Cancer Chemotherapy and Pharmacology, 2012, 70(4):p.611-615.

[24] Ma X , Huang J , Wu X ,et al. Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis[J]. Cancer Biomarkers, 2014, 14(4):267-77.

[25] Jia,Shen, Changling,et al. Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis.[J]. Oncotargets & Therapy, 2019.

[26] Bossi P , Locati L , Licitra L .Emerging tyrosine kinase inhibitors for head and neck cancer[J].Expert Opin Emerg Drugs, 2013, 18(4):445-459.

[27] Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma[J].Cancer Medicine, 2020, 9(5):1721-1732.

[28] Yang Y , Fang W , Ma Y . Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J].Retour au numéro, 2018.

[29] Hsu C , Lee S H , Ejadi S ,et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study[J].Journal of Clinical Oncology, 2017, 35(36):4050-4056.